RT Journal Article
SR Electronic
T1 Survival and 30-days hospital outcome in hospitalized COVID-19 patients in Upper Egypt: Multi-center study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.26.20180992
DO 10.1101/2020.08.26.20180992
A1 Hussein, Aliae AR Mohamed
A1 Galal, Islam
A1 Mohamed, Mohammed Mustafa Abdel Rasik
A1 Eltaher AA Ibrahim, Mohamed
A1 Ahmed, Shazly B
YR 2020
UL http://medrxiv.org/content/early/2020/09/01/2020.08.26.20180992.abstract
AB Background Defining the clinical features and associated outcomes of patients diagnosed with corona virus disease (COVID-19) is fundamental to improving our understanding and adequate management of this illness. The aim of this study was to identify the demographic data, underlying comorbidities and the mortality related factors of hospitalized patients with COVID-19 in Upper Egypt.Patients and methods 1064 cases consecutively admitted to isolation hospitals in Upper Egypt. All cases had confirmed COVID-19 infection. The electronic records of the patients were retrospectively revised and the demographic data, clinical manifestations, qSOFA score on admission and 30 days-outcome (ICU admission, death, recovery, referral or still in hospital) were analyzed. Overall cumulative survival in all patients and those > or < 50 years were calculated.Results 49.2% of the study population were males and 50.8% were females with mean age 49.4±17.8 years-old. On admission, 83.9% were stable with qSOFA score <1, 3% required non-invasive mechanical ventilation, and 2.1% required O2 therapy. Within 30 days, 203 cases (19.1%) required admission to ICU. Death was recorded in 11.7% of cases, 28.7% recovered, 40.5% referred and 19.2% were still under treatment. Determinants of ICU admission and survival in the current study were age > 50, respiratory rate > 24/minute, SaO2 < 89%, qSOFA >1 and need for O2 therapy or NIV. The cumulative survival was 75.3% with the mean survival was 28.1, and 95.2% overall survival was recorded in those aged ≤50 years.Conclusions Age older than 50 years old, those with pre-existing DM, initial qSOFA score, requirement for O2 therapy and NIV from the first day of hospital admission may be associated with unfavorable 30 days- in hospital outcome of COVID-19.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04488588Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:17300455All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAvailable on request